Usefulness of a New Immunoradiometric Assay of HCV Core Antigen to Predict Virological Response during PEG-IFN/RBV Combination Therapy for Chronic Hepatitis with High Viral Load of Serum HCV RNA Genotype 1b

We investigated the clinical usefulness of a new immunoradiometric (IRM) assay of hepatitis C virus (HCV) core antigen in predicting virological response during pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy for chronic hepatitis with high viral loads of serum HCV RNA genotype 1b. Thirty-nine patients received a regimen of PEG-IFNα-2b (1.5 µg/kg/week s.c.) in combination with RBV (600–1,000 mg/day). Of the 39 patients, 18 (46.2%) achieved sustained virological response (SVR), 11 (28.2%) attained partial response (PR) and 10 (25.6%) showed no response (NR). Four weeks after the start of therapy, 1- and 2-log reductions in the amount of HCV core antigen were observed in 20 (2/10) and 0% (0/10) showing NR, 91 (10/11) and 63.6% (7/11) with PRs, and 88.9 (16/18) and 55.6% (10/18) of patients with SVR, respectively. The 1- and 2-log reductions 4 weeks after the start of therapy were not a definingcondition for PR and SVR. The amount of HCV core antigen was significantly different between SVR and PR patients on days 1 and 7, and between patients with NR and SVR at all points of time. In conclusion, this new IRM assay is useful in predicting virological response during PEG-IFN/RBV therapy.

[1]  Yoshiyuki Suzuki,et al.  Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia , 2007, Intervirology.

[2]  Ahmed El-Shamy,et al.  Prediction of Efficient Virological Response to Pegylated Interferon/Ribavirin Combination Therapy by NS5A Sequences of Hepatitis C Virus and Anti‐NS5A Antibodies in Pre‐Treatment Sera , 2007, Microbiology and immunology.

[3]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[4]  Hideji Nakamura.  Early prediction of sustained viral responder and non-responder during interferon and ribavirin combination therapy in chronic hepatitis C. , 2005, Hepatology Research.

[5]  M. Kohara,et al.  Usefulness of a new immuno‐radiometric assay to detect hepatitis C core antigen in a community‐based population , 2005, Journal of viral hepatitis.

[6]  P. Ferenci.  Predictors of response to therapy for chronic hepatitis C. , 2004, Seminars in liver disease.

[7]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[8]  M. Buti,et al.  Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases , 2003, Hepatology.

[9]  G. Davis.  Monitoring of viral levels during therapy of hepatitis C , 2002, Hepatology.

[10]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[11]  A. Widell,et al.  Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window‐phase , 2002, Transfusion medicine.

[12]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[13]  A. Neumann,et al.  Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. , 2001, Gastroenterology.

[14]  S. Yagi,et al.  Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA , 2000, Hepatology.

[15]  M. Mizokami,et al.  Quantification of serum HCV core antigen by a fluorescent enzyme immunoassay in liver transplant recipients with recurrent hepatitis C--clinical and virologic implications. , 1999, Transplantation.

[16]  F. Komatsu,et al.  Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients. , 1999, Liver.

[17]  S. Yagi,et al.  Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core Antigen , 1999, Journal of Clinical Microbiology.

[18]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[19]  A. Neumann,et al.  Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.

[20]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[21]  M. Kohara,et al.  Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. , 1995, Journal of hepatology.